United States v. Abdeljawad

CourtCourt of Appeals for the Tenth Circuit
DecidedNovember 27, 2019
Docket18-2121
StatusUnpublished

This text of United States v. Abdeljawad (United States v. Abdeljawad) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Abdeljawad, (10th Cir. 2019).

Opinion

FILED United States Court of Appeals UNITED STATES COURT OF APPEALS Tenth Circuit

FOR THE TENTH CIRCUIT November 27, 2019 _________________________________ Elisabeth A. Shumaker Clerk of Court UNITED STATES OF AMERICA,

Plaintiff - Appellee, No. 18-2121 v. (D.C. No. 1:15-CR-03394-WJ-1) (D.N.M.) FIDAL ABDELJAWAD,

Defendant - Appellant. _________________________________

ORDER AND JUDGMENT * _________________________________

Before BACHARACH, McHUGH, and SEYMOUR, Circuit Judges. _________________________________

This appeal involves sentencing for drug crimes. When deciding on

the sentence, district courts ordinarily consider the potency and weight of

the drugs. To aid courts in considering potency and weight, the U.S.

Sentencing Commission has created guidelines. But new drugs frequently

enter the market, 1 creating gaps in the Sentencing Commission’s

* This order and judgment does not constitute binding precedent except under the doctrines of law of the case, res judicata, and collateral estoppel. But the order and judgment may be cited for its persuasive value if otherwise appropriate. Fed. R. App. P. 32.1(a); 10th Cir. R. 32.1(A).

1 See United States v. Ono, 997 F.2d 647, 649 (9th Cir. 1993) (noting that “[t]he illicit drug industry is constantly changing and experimenting to create new ‘designer drugs,’” preventing the Sentencing Commission from handiwork. An example is the emergence of synthetic marijuana, which

was involved in Mr. Abdeljawad’s crimes. Synthetic marijuana is the

combination of synthetic cannabinoid, which is a controlled substance, and

inert plant material.

At the time of Mr. Abdeljawad’s sentencing, the guidelines did not

specify how to consider mixtures containing synthetic cannabinoid. So the

district court had to decide how to handle this gap in the guidelines. The

district court decided to handle this gap by excluding the inert plant

material and considering only the synthetic cannabinoid. Mr. Abdeljawad

argues that the district court should have included the inert plant material.

We disagree.

1. When gaps exist, the district court must find an equivalent drug from a list of controlled substances.

To decide on the sentence, the district court must determine the

guideline range for the applicable year. (Here, the applicable year is

2017.) 2 To determine this range, the court considers the drug weight. See

U.S. Sentencing Guidelines Manual § 2D1.1 cmt. n.5 (U.S. Sentencing

Comm’n 2016).

“list[ing] or predict[ing] every potential chemical composition that yields a new drug”). 2 In 2017, however, the U.S. Sentencing Commission did not publish a new set of the guidelines. The Commission instead continued to use the 2016 version throughout 2017.

2 But different drugs may weigh the same yet differ dramatically in

potency. Given these variations in potency, the Sentencing Commission

provides two lists that guide consideration of relatively common drugs:

(1) a drug-quantity table and (2) a drug-equivalency table. Id. § 2D1.1(c)

(drug-quantity table), cmt. n.8(D) (drug-equivalency table). The drug-

quantity table lists the base-offense level, which is triggered by the type

and weight of the controlled substance; and the drug-equivalency table

provides a list to convert the weights for various drugs into a uniform

system of measurement. But many drugs are omitted from both lists.

When the defendant’s drug is omitted, it must be compared to one of

the drugs on the Sentencing Commission’s lists. 3 For this comparison, the

Sentencing Commission specifies that both the actual drug and the listed

drug must be “controlled substance[s].” Id. § 2D1.1 cmt. n.6. The actual

3 The application note requires comparison to “the most closely related controlled substance referenced in this guideline.” U.S. Sentencing Guidelines Manual § 2D1.1 cmt. n.6 (U.S. Sentencing Comm’n 2016) (emphasis added). Some circuits treat the italicized phrase (“in this guideline”) as a reference to the drug-equivalency table. United States v. Ramos, 814 F.3d 910, 918 (8th Cir. 2016). Other circuits treat this phrase as a reference to either of the two lists (either the drug-quantity table or the drug-equivalency table). United States v. Moreno, 870 F.3d 643, 645– 46 (7th Cir. 2017); United States v. Giggey, 867 F.3d 236, 239 (1st Cir. 2017).

This difference would not affect our analysis. Both sides agree that the court had to compare Mr. Abdeljawad’s drug with THC (as well as marijuana). THC appears in the list for the drug-equivalency table but not the list for the drug-quantity table.

3 drug is described as “a controlled substance that is not specifically

referenced in this guideline.” Id. (emphasis added). The court must

compare this “controlled substance” to another “controlled substance” that

is “referenced in this guideline.” Id.

2. The district court considered only the synthetic cannabinoid (without the plant material) to make the comparison.

This case requires the Court to decide how to conduct this

comparison when the case involves synthetic marijuana. Until recently,

marijuana consisted of plant material that naturally contains THC. Now,

however, marijuana can also be synthetic. Synthetic marijuana is a mixture

of synthetic cannabinoid (a synthetic substance that binds to the same brain

cell receptors as THC) and inert plant material. The inert plant material

serves as a carrier medium for someone to use the synthetic cannabinoid.

Prior to 2018, natural marijuana and THC appeared in the Sentencing

Commission’s lists, but synthetic cannabinoid was omitted. U.S.

Sentencing Guidelines Manual § 2D1.1(c) (drug-quantity table), cmt.

n.8(D) (drug-equivalency table) (U.S. Sentencing Comm’n 2016).

Notwithstanding this omission, the district court had to calculate the

converted drug weight of Mr. Abdeljawad’s drug in order to use the drug-

quantity table.

To calculate the converted drug weight, the court had to determine

which listed controlled substance on the drug-equivalency table most

4 closely resembled Mr. Abdeljawad’s drug. Among the possibilities, Mr.

Abdeljawad picked marijuana and the government picked THC.

3. The inert plant material was properly excluded from the phrase “controlled substance that is not specifically referenced.”

Before these drugs could be compared, the district court had to apply

Application Note 6, which instructs courts on how to calculate the weight

of drugs omitted from the Sentencing Commission’s lists. The application

note refers to a drug omitted from these lists as “a controlled substance

that is not specifically referenced in this guideline.” U.S. Sentencing

Guidelines Manual § 2D1.1 cmt. n.6 (U.S. Sentencing Comm’n 2016).

The district court had to interpret this phrase in the context of Mr.

Abdeljawad’s case. Does this phrase refer to

 just the synthetic cannabinoid or

 the mixture of the synthetic cannabinoid and the inert plant material?

The district court decided to consider just the synthetic cannabinoid

Free access — add to your briefcase to read the full text and ask questions with AI

Related

K Mart Corp. v. Cartier, Inc.
486 U.S. 281 (Supreme Court, 1988)
Chapman v. United States
500 U.S. 453 (Supreme Court, 1991)
United States v. Randall
472 F.3d 763 (Tenth Circuit, 2006)
United States v. Nacchio
573 F.3d 1062 (Tenth Circuit, 2009)
United States v. Rivera-Oros
590 F.3d 1123 (Tenth Circuit, 2009)
United States v. Pete Upthegrove
974 F.2d 55 (Seventh Circuit, 1992)
United States v. Marrufo
661 F.3d 1204 (Tenth Circuit, 2011)
United States v. Leal-Vega
680 F.3d 1160 (Ninth Circuit, 2012)
United States v. Le'Ann Koss
812 F.3d 460 (Fifth Circuit, 2016)
United States v. Earl Ramos
814 F.3d 910 (Eighth Circuit, 2016)
United States v. Giggey
867 F.3d 236 (First Circuit, 2017)
United States v. Michael Moreno
870 F.3d 643 (Seventh Circuit, 2017)
United States v. Archuleta
865 F.3d 1280 (Tenth Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Abdeljawad, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-abdeljawad-ca10-2019.